These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11854887)

  • 1. Point-of-care coagulation monitoring for cardiovascular patients: past and present.
    Shore-Lesserson L
    J Cardiothorac Vasc Anesth; 2002 Feb; 16(1):99-106. PubMed ID: 11854887
    [No Abstract]   [Full Text] [Related]  

  • 2. Evidence based coagulation monitors: heparin monitoring, thromboelastography, and platelet function.
    Shore-Lesserson L
    Semin Cardiothorac Vasc Anesth; 2005 Mar; 9(1):41-52. PubMed ID: 15735843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Difference in examination of coagulation function in heparin anticoagulant therapy between point of care tests and automatic coagulation analyzer].
    Li J; Cong YL; Tu GH; Yang L; Zhu BB; Jin L
    Zhonghua Yi Xue Za Zhi; 2007 May; 87(18):1269-71. PubMed ID: 17686264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test.
    Wallock M; Jeske WP; Bakhos M; Walenga JM
    Perfusion; 2001 Mar; 16(2):147-53. PubMed ID: 11334198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are the point-of-care diagnostics MULTIPLATE and ROTEM valid in the setting of high concentrations of heparin and its reversal with protamine?
    Gertler R; Wiesner G; Tassani-Prell P; Braun SL; Martin K
    J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):981-6. PubMed ID: 21315618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest-POC-Hi.
    Hellstern P; Bach J; Simon M; Saggau W
    J Extra Corpor Technol; 2007 Jun; 39(2):81-6. PubMed ID: 17672188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does heparin pretreatment affect the haemostatic system during and after cardiopulmonary bypass?
    Brinks HJ; Weerwind PW; Bogdan S; Verbruggen H; Brouwer MH
    Perfusion; 2001 Jan; 16(1):3-12. PubMed ID: 11192305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point-of-care coagulation testing and transfusion algorithms.
    Enriquez LJ; Shore-Lesserson L
    Br J Anaesth; 2009 Dec; 103 Suppl 1():i14-22. PubMed ID: 20007984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II.
    Koster A; Meyer O; Fischer T; Kukucka M; Krabatsch T; Bauer M; Kuppe H; Hetzer R
    J Thorac Cardiovasc Surg; 2001 Dec; 122(6):1254-5. PubMed ID: 11726910
    [No Abstract]   [Full Text] [Related]  

  • 10. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
    Despotis GJ; Joist JH
    J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis.
    Follis F; Schmidt CA
    Ann Thorac Surg; 2000 Dec; 70(6):2173-81. PubMed ID: 11156153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Another perspective on monitoring anticoagulation therapy.
    Burnakis TG
    Ann Pharmacother; 1995 Oct; 29(10):1045-6. PubMed ID: 8845545
    [No Abstract]   [Full Text] [Related]  

  • 14. [Anticoagulant therapy and cardiopulmonary bypass].
    Lespron Robles Mdel C; Molina Méndez J
    Arch Cardiol Mex; 2007; 77 Suppl 4():S4-185-93. PubMed ID: 18938724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin management test versus activated coagulation time during cardiovascular surgery: correlation with anti-Xa activity.
    Fitch JC; Geary KL; Mirto GP; Byrne DW; Hines RL
    J Cardiothorac Vasc Anesth; 1999 Feb; 13(1):53-7. PubMed ID: 10069285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coagulation assays.
    Bates SM; Weitz JI
    Circulation; 2005 Jul; 112(4):e53-60. PubMed ID: 16043649
    [No Abstract]   [Full Text] [Related]  

  • 17. Monitoring of systemic anticoagulation during cardiopulmonary bypass.
    Bidstrup BP
    Ann Thorac Surg; 1996 Mar; 61(3):781-2. PubMed ID: 8619692
    [No Abstract]   [Full Text] [Related]  

  • 18. The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation.
    Koster A; Despotis G; Gruendel M; Fischer T; Praus M; Kuppe H; Levy JH
    Anesth Analg; 2002 Jul; 95(1):26-30, table of contents. PubMed ID: 12088937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Point of care technologies.
    Gilbert HC; Szokol JW
    Int Anesthesiol Clin; 2004; 42(2):73-94. PubMed ID: 15087742
    [No Abstract]   [Full Text] [Related]  

  • 20. Portable cardiopulmonary support (ECPS) in the emergency room.
    Ullrich R; Kneifel W; Fuchs M; Hödl W; Zimpfer M; Germann P
    Anaesthesia; 1998 May; 53 Suppl 2():6-8. PubMed ID: 9659042
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.